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Abstract: This paper reports a superficial morphological modification of the hydroxyapatite grains obtained by in situ deposition of Ag 
nanoparticles on natural origin calcium phosphate powder. Ceramic material was prepared in three stage bone treatment, including hydrolysis 
with a lactic acid, pre-calcination, and proper calcination. Subsequently, the Ag nanoparticles were synthesized by chemical reduction of Ag+ 
by sodium borohydride in a solution of polyvinylpyrrolidone and in presence of hydroxyapatite. Such-prepared materials were investigated with 
X-ray diffraction, Fourier-transformed infrared spectroscopy, atomic absorption spectrometry and scanning electron microscopy with energy 
dispersive spectroscopy. Furthermore, Ca/P molar ratio was calculated and microbiological tests were performed to investigate materials 
antimicrobial activity. The appearance of Ag nanoparticles located on phosphate surface was confirmed by SEM analysis, and no chemical 
bonding with hydroxyapatite was recorded by IR and XRD techniques. Additionally, the biological assessment revealed bactericidal effect on 
Escherichia coli and Staphylococcus aureus, while slightly affected on Enterococcus faecalis viability. 
 





S the civilizational development progresses, the num-
ber of people aged 65 and above increases making 
the population aging a global issue.[1–2] The number of 
retirement-age people is predicted to double by 2050, thus 
the increasing demand for implant materials resulting from 
population aging and unceasing health-care improvement 
as well is understandable. The main requirements of 
biomedical materials relating to their biological properties 
and strength, among which the most important are 
biomechanical compatibility, biofunctionality, bioactivity, 
and for materials implanted for a limited time, also 
bioresorption.[3–4] However, interference with the patient's 
body often leads to postoperative infections, which entails 
re-surgery. Specially design biomaterials combining 
features which help maintain the properties and archit-
ecture of the natural tissue, possessing antimicrobial 
properties providing sterility during the adaptation of an 
implant and enhancing healing of the postoperative 
wound, can be the reasonable solution for the re-surgeries 
problem. 
 The highest biocompatibility and ability to support 
cell growth among all implant materials were found in the 
hydroxyapatite bioceramic which is generally recognized as 
a non-toxic and biologically active material.[5–7] Never-
theless, bioceramics have no antimicrobial properties, thus 
re-surgery caused by infections related to the opening of 
tissues during the implantation procedure is often needed 
despite the full biocompatibility of material. This may be 
resolved by the use of ions and metal particles providing 
biocidal properties. If they were used for implantation 
purposes together with the biocompatible bioceramics, a 
locally antimicrobial and bioactive material could be 
introduced into the organism. Silver is an element with 
strong biocidal properties associated with the process of 
gradual oxidation of silver atoms on the sample surface in 
the presence of oxygen and atmospheric water. Silver ion 
on animal biologically active surfaces is deactivated 
through the reduction to insoluble forms, while nanosized 
silver does not react with salts in biological liquids, which 
accounts for its extraordinary disinfecting efficacy. The 
biocidal activity of silver nanoparticles depends on their 
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contains atoms that can react with the environment. Still, 
as the size of the silver crystalline network increases, the 
number of inactive atoms grows as well because part of the 
atoms is locked inside the crystallite and thus unable to 
react with the environment.[8–10] It has been demonstrated 
that silver, apart from its antibacterial properties, in the 
hydroxyapatite/Ag powders significantly improves a 
number of unfavorable mechanical properties. Hydroxy-
apatite modified with metallic silver sintered in an air 
atmosphere has a higher modulus of elasticity and lower 
hardness than hydroxyapatite itself. Studies performed by 
M. Diaz confirmed the antibacterial activity of the HA/Ag+ 
powders towards Staphylococcus aureus, Pneumococcus, 
and Escherichia coli.[11] X. Zhang et al. described in their 
studies HA/Ag+ materials prepared using mechanochemical 
methods from a mixture of hydroxyapatite and silver oxide 
powders sintered at 1250 °C.[12] Hydroxyapatite containing 
metallic silver can be obtained through the chemical 
reduction using polyvinyl alcohol as the stabilizer and 
dimethylformamide as the reducing agent as well.[13] Silver-
modified hydroxyapatite can also be obtained using the  
sol-gel method with silver oxide and citric acid in the 
presence of ammonia solution.[14] Studies carried out by 
Rameshbabu et al.[15] and Fakharzadeh et al.[16] demonst-
rated the increased efficacy of implanTable biomaterials 
used to manage bone damage that contains silver. The 
literature contains numerous examples of ways to obtain 
silver compound-modified bioceramics but there are no 
records describing calcium phosphates modified with silver 
nanoparticles. It is worth noting that even high biocom-
patibility and proper fitting of the implant to the bone 
defect, do not overcome the fact that every intervention in 
the living organism causes a number of changes in the 
patient's body. Furthermore, one of the obstacles of all 
types of surgery is postoperative complications consisting 
mainly of inflammation at the surgical site. In order to 
minimize the probability of such a phenomenon, the 
authors plan to developed materials antibacterial and 
antifungal properties by introducing nanosized silver with 
increased antimicrobial properties as compared to silver 
ions. In general, these nanoparticles do not affect 
mammalian cells containing peptidoglycans. However, it is 
proved, that metallic nanoparticles destroy the bacteria 
cells in a few stages including penetration of its interior, 
surrounding the bacteria with tight layer, blocking flagella, 
fimbriae, and pils, leading to the inability of bacteria to 
move, and eliminating contact with other bacteria cells 
resulting in no genetic material exchanging and finally 
losing the ability to reproduction. Based on previous 
original studies by the authors,[17] this paper attempts to 
obtain hydroxyapatite crystals coated with silver 
nanoparticles. Metallic nanoparticles were obtained in a 
chemical reduction in the presence of hydroxyapatite (in 
situ method). The procedure resulted in carbonated 
hydroxyapatite (cHA) powders with silver nanoparticles 
without significant morphological changes to the original 
material. The presented study on the synthesis and 
application of this type of biomaterial may prove to become 
an important step towards a new generation of bioactive 
materials intended to medical and dental application that 
are burdened with only a small probability of postoperative 
complications; low costs, simple process conditions, and no 
need for complicated equipment are unquestionable 
advantages of the proposed technology. 
 
MATERIALS AND METHODS 
Natural hydroxyapatite was prepared in a three-stage 
process involving hydrolysis with the lactic acid, 
precalcination (650 °C), and proper calcination (900 °C) in 
chamber furnace in an air atmosphere as described by 
Sobczak-Kupiec et al.[18] The cHA surface was modified by 
obtaining silver nanoparticles (AgNPs) in situ. To this end, 6 
g of natural origin hydroxyapatite (sieve fraction below 65 
μm) was introduced into 40 mL of 3 % water solution of 
polyvinylpyrrolidone (PVP, M.W. 8000, Alfa Aesar, reagent 
grade) while stirring. Next, silver(I) nitrate (POCH, reagent 
grade) was introduced into the suspension in the amount 
equivalent to Ag concentrations of 500 ppm (0.0394 g) 
(cHA500) and 1000 ppm (0.0788 g) (cHA1000). A reducing 
agent, sodium borohydride (POCH, reagent grade) at a 
molar ratio of 1:10 to silver ions (0.1490 g or 0.0279 g) was 
dissolved in 10 mL of the PVP solution (3 %) and added 
dropwise into the prepared mixture. The modification was 
introduced at room temperature with stirring continued for 
15 minutes after the completion of the introduction of the 
reducing agent. Immediately after the NaBH4 solution was 
dosed, the suspension changed its color from white to 
brown-grey. The suspension was eventually filtered, 
flushed with deionized water, and dried at room 
temperature. 
 The resulting materials were subjected to X-ray 
diffraction XRD analysis to determine the phase 
composition of the materials, scanning electron microscopy 
with X-ray microanalysis EDS, spectrum analysis using the 
FT-IR method, determination of silver content using atomic 
absorption spectroscopy (AAS) with Analyst 300 by 
PerkinElmer, and determination of Ca and P in accordance 
with Polish standards PN-R-64803:199P and PN-80/C-
87015.[19,20] Qualitative phase analysis of prepared 
materials was performed using powder X-ray Diffrac-
tometry utilizing XRD - Philips X'Pert diffractometer with Cu 
Kα radiation (λ = 0.15418 nm), equipped with graphite 
monochromator PW 1752/00 operating at 40 kV and 30 
mA. Scans were performed over Bragg-Brentano geometry 
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using standard holder (20 ×10×2 mm). The Match! 
software version 3.6 with reference patterns calculated 
from the COD database was performed for phase 
identification from powder diffraction data. In order to fully 
characterize the chemical composition of cHA and 
cHA/AgNPs materials, Fourier-transform infrared spectro-
scopy was utilized. Materials were investigated with 
Scimitar Series Digilab FT-IR Spectrometer in the range of 
middle infrared of 400-4000 cm–1. Morphology and 
chemical composition of cHA samples placed on the copper 
holder and sputter–coated with gold were investigated 
with scanning electron microscope (SEM) with energy 
dispersive detector under vacuum. SEM images were 
obtained using a JEOLJSM-5510L with energy dispersive 
spectroscopy (EDS) at the accelerating voltage of 15 kV. 
Calcium content in all powders was assayed using 
complexometric titration with ethylenediaminetetraacetic 
acid (EDTA). The method employed the mineralization of 
the sample in nitric acid, precipitating phosphates with 
bismuth(III) nitrate, and then determining calcium by EDTA 
titration in the presence of indicator (calcein and 
thymolphthalein). Phosphorus content in the material was 
determined using the spectrophotometric method. This 
method involves the production of a phosphorus-
vanadium-molybdenum complex and the photometric 
measurement of the optical density at the wavelength of 
430 nm. The analysis was performed on spectrophoto-
meter Evolution 201 by ThermoScientific.  
 To fully address the question, whether obtained 
surface-modified carbonated hydroxyapatite have antibac-
terial activity, we performed antimicrobial studies against 
three respective pathogenic organisms, Staphylococcus 
aureus (ATCC 25923), Escherichia coli (ATC 25922) and 
Enterococcus faecalis (ATCC 29212). S. aureus is an 
abundant Gram(+) bacteria, typically found in nasal 
passages and ears of patients.[21] This bacteria is recognized 
to be a significant factor initializing localized and systemic 
infections including osteomyelitis[22] and chronic wound 
infection,[23] as well as dental implant infections.[24] 
Infections caused by Gram(–) bacteria account for ~15 % of 
Orthopaedic Implant Infections (OII) which is related with 
the increase in treatment failure risk and E. coli is the 
second most common Gram(–) bacteria causing OII.[25] The 
Gram(+) bacteria E. faecalis are usually found in the 
gastrointestinal tract of humans. Nonetheless, colonization 
of the genitourinary tract and the oral cavity are also 
reported. E. faecalis is the most common bacteria found in 
infected root canals and marginal periodontitis.[26] Prior to 
the experiments, microbial suspensions were adjusted to a 
density of 1×105 CFU/mL obtained from 18 h bacterial 
cultures developed on solid media. The antimicrobial 
studies against E. coli and S. aureus were tested on Muller 
Hinton Agar medium, while Muller Hinton Agar containing 
5 % of sheep blood was used in case of E. faecalis. The 
tested powders were suspended in DMSO at the 
concentration of 100 mg/mL. 100 μL of prepared material 
was then placed in triplicate in test tubes containing 100 μL 
of bacterial suspension and 800 μL 0.9 % NaCl and 
incubated in 37 °C for 24 hours. The test tubes containing 
100 μL of NaCl solution instead of the tested substances 
were used as a growth control. After the incubation, the 
number of colonies grown was counted and compared to 
the control (C) that represented 100 % growth. The tests 
were carried out based on the procedures included in the 
Polish standards PN-EN 1040:2006E and PN-EN 
1276:2010E.[27,28] Additionally, the agar diffusion assay was 
used to test the sensitivity of bacteria to the prepared 
hydroxyapatite powders modified with silver nanoparticles. 
In this method discs to test the extent to which bacteria 
strains are affected by tested materials. If the bacterial 
strain is susceptible to the tested substances, then a wide 
ring of no bacterial growth appears on the agar plate, while 
an ineffective antimicrobial substance will show no change 
in the surrounding media at all. With this method, microbial 
suspensions corresponding to a 0.5 McFarland density was 
seeded into sterile Petri plates containing Mueller Hinton 
agar medium. Then, 10 μL of 100 mg/mL hydroxyapatite-
AgNPs suspensions were loaded on 9 mm diameter sterile 
disks (in triplicate), which next where placed on the Petri 
dish and incubated for 24 h at 37 °C. The results were 
recorded by observing the inhibition zone. 
 The significant differences between control and 
treated cells were statistically analyzed by independent-
sample Student’s t-test. The analysis was conducted in 
Statistica 13.1 PL software (StatSoft, Poland). Results were 
considered statistically significant when p < 0.05. 
 
RESULTS 
X-ray Diffraction Analysis 
In order to determine phase composition of the analyzed 
materials X-ray diffractometry was used. X-ray diffraction 
patterns of pure cHA and cHA/NPs powders are shown in 
Figure 1. 
 The diffraction patterns suggest that the cHA was 
highly crystalline, which was indicated by the presence of 
sharp peaks. The analysis has demonstrated that the only 
crystalline phase in the material is hydroxyapatite. 
FT-IR Analysis 
In order to fully characterize chemical composition of cHA 
and cHA/AgNPs materials Fourier-transform infrared 
spectroscopy was utilized. IR spectra of cHA and 
cHA/AgNPs powders are shown in Figure 2 and summarized 
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 In the 1000–1100 cm−1 region, bands located at 1037 
cm−1 and 1090 cm−1 were attributed to the ν3 triply 
degenerate asymmetric stretching mode of PO43−. The 
transmittance band at 963 cm–1 was assigned to the ν4 
bending vibration of phosphate (PO43–). Furthermore, two 
distinctive peaks observed at 627 cm−1 and 3568 cm−1 were 
attributed to in-plane vibration δ of OH− and νs stretching 
mode of the structural OH− anion, respectively. Two sharp 
and intensive bands in the low wavenumber region at 601 
cm−1 and 568 cm−1 correspond to ν4 triply degenerate 
bending mode of PO43−, while the band at 470 cm−1 
represents ν2 doubly degenerate bending mode of PO43−. 
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Additionally, bands corresponding to the ν3 stretching 
mode of CO32− were detected at 1489 cm−1, 1413 cm−1. The 
weak bands at and 869 cm−1 and 769 cm−1 were also 
associated with presence of carbonate group in cHA 
structure and referring to ν2 bending mode, and ν4 in-plane 
deformation bending mode of CO32−, respectively.  
Composition Analysis 
The AAS determined the amount of silver deposited on the 
surface of HA during the production of Ag nanoparticles 
with the in situ method. Calcium and phosphorous content 
in all powders was assayed using complexometric titration 
and spectrophotometric method, respectively. Thanks to 
the determination of calcium and phosphorus content in 
apatite, the molar ratio of Ca/P in the materials was 
calculated. Results are summarized in Table 2. 
 Molar ratios of Ca to P calculated in accordance with 
Polish Standards were in the range from 1.68 ± 0.11 to 1.75 
± 0.03. This demonstrates the receiving of hydroxyapatite 
of slightly different composition than the stoichiometric 
one that is characterized by Ca/P molar ratio equal to 1.67. 
The total silver content in the materials was 3.44 ± 0.14 
mg/g for cHA500 and 5.46 ± 0.36 mg/g for cHA1000. 
Additionally, based on the calculated silver con-tent to the 
introduced value, the yield of the modification of calcium 
phosphate with AgNPs was calculated. As shown in Table 2, 
the Ca/P molar ratio in natural cHA does not change 
significantly after the in situ reduction of silver ions. The 
yield of the modification was 82.56 ± 4.07 % and 65.51 ± 
6.59 %, for cHA500 and cHA1000, respectively. 
SEM-EDS Analysis 
SEM imaging gave insight into hydroxyapatite structure 
regarding particle size and shape. The SEM images of 
natural origin cHA and cHA/NPs materials taken with 
different magnifications are shown in Figure 3. 
 Figure 3A shows SEM images of natural origin HA 
surface. SEM imaging shows heterogeneity in cHA crystals 
size and shape. Spot EDS analysis indicated the presence of 
phosphorus, calcium, and carbon, which is typical of natural 
hydroxyapatite. The presence of copper and gold in EDS 
spectra was associated with the type of holder used in the 
analysis and the sputtering of powders with the conductive 
gold layer. SEM analysis of different points at materials 
surface (Figure 3D, 3G) show spherical agglomerates on 
apatite surface. Representative SEM images show that in 
both materials the synthesized AgNPs were approximating 
a spherical shape. In the case of sample cHA500 spherical 
Table 1. IR band assignment of the samples. 
Wavenumber / cm–1 Peak assignment References 
3568 νs stretching mode of O–H [29,30] 
1489 ν3 stretching mode of CO32− [29–31] 
1413 ν3 stretching mode of CO32− [32–34] 
1090 ν3 triply degenerate asymmetric stretching mode of PO43− (P–O) [19,30,32] 
1032 ν3 triply degenerate asymmetric stretching mode of PO43− (P–O) [30] 
963 ν1 nondegenerate symmetric stretching mode of PO4 3− (P–O) [30,34,35] 
869 ν2 bending mode of CO32−  [30–32] 
769 ν4 in-plane deformation bending mode of CO32− (O–C–O) [36,37] 
627 δ in-plane vibration of OH- [38,39] 
601 ν4 triply degenerate bending mode of PO43− (O–P–O) [29,32] 
568 ν4 triply degenerate bending mode of PO43− (O–P–O) [30,32] 
470 ν2 doubly degenerate bending mode of PO43− (O–P–O) [35,40] 
 
 
Table 2. Quantitative composition analysis of tested samples. 
CPs material Determined Ca/P molar ratio Content of Ag in the sample / mg/g Adsorbed amount of Ag / % 
cHA 1.75 ± 0.03 0.00 0.00 
cHA500 1.74 ± 0.08 3.44 ± 0.14 82.56 ± 4.07 
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particles were found much smaller with a diameter of 
about 50 nm as shown in Figure 3D. In the case of sample 
cHA1000, the nanoparticles diameters were about 100 nm. 
What is important, the spot EDS analysis of the surfaces of 
modified phosphates confirmed the presence of silver in 
the samples. 
Antibacterial Activity 
Figure 4 exemplifies the bacteria growth of test species 
exposed to powders expressed as a percentage of viability, 
whose high percentage indicates poor antibacterial activity 
of tested materials. The symptoms of strong antibacterial 
reactivity were shown both in E. coli and S. aureus; 
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however, in case of E. coli both tested materials caused 100 
% of growth inhibition after only 15 minutes of incubation. 
Generally, E. coli and S. aureus were significantly more 
sensitive to exposure to cHA/NPs powders than the E. 
faecalis strains. In the case of cHA500, E. faecalis viability 
was 93.2 % ± 2.4, 87.1 % ± 3.1 and 81.8 % ± 1.7 after 15, 30 
and 60 minutes incubation time, respectively. Additionally, 
it was observed that the antibacterial activity against S. 
aureus and E. faecalis were slightly depended on the silver 
nanoparticles concentration. Both AgNPs doses elicited the 
similar antibacterial response. Moreover, it has been 
observed that the growths of both, S. aureus and E. faecalis 
were slightly affected by increasing the incubation time. 
 Disc diffusion test results (Figure 5) revealed that 
both samples exhibited high antimicrobial activity against 
E. coli and S. aureus strains, however, no inhibition zone 
was observed in the case of E. faecalis, which is consistent 
with previous antibacterial studies. Due to the presence of 
higher AgNPs concentration cHA1000 (E. coli 13.0 ± 0.22 
mm and S. aureus 14.5 ± 0.17 mm) exhibited maximum 
activity as compared to cHA500 for both microorganism (E. 
coli 12.5 ± 0.20 mm and S. aureus 13.0 ± 0.17 mm), as 
opposed to E. faecalis, in case of which there was no zone 
of bacterial growth inhibition. 
 
DISSCUSSION 
X-ray diffraction phase composition analysis of the cHA and 
cHA/AgNPs powders demonstrated high crystallinity of the 
ceramics obtained in the three-step treatment of the 
material of animal origin. Applying the search-match 
program for all patterns, the only phase present in samples 
is found to be hydroxyapatite. The XRD analysis did not 
reveal TCP (tricalcium phosphate) formation. However, 
studies by Qian Jun He et al. confirm that the phase 
transition of carbonate hydroxyapatite may take place in a 
broad range of temperatures different to the temperatures 
specific for stoichiometric hydroxyapatite.[41] On the other 
hand, despite the better thermal stability and crystallinity, 
stoichiometric hydroxyapatite offers poorer bioactivity and 
osteoconductivity as compared to carbonate HA.[42] 
 IR analysis confirmed the presence of CO32– groups 
in the analyzed materials. What is more, the experiments 
suggest conclusions that the phosphates are subject to 
isomorphous replacement of the phosphate group both at 
position A and B, which is indicated by ν3 stretching mode 
of CO32− (A-type or B-type), ν2 bending mode of CO32− (A-
type) and ν3 stretching mode of CO32− (B-type). The 
absorption band at 869 cm−1 is typical of CO32− anions, 
which partially take up positions of hydroxyl groups (A-
type), while bands at 1489 cm−1 and 1413 cm−1 show partial 
replacement of phosphate groups (B-type). Based on the 
intensity ratio of individual absorption bands of the CO32−, 
the IR analysis did not demonstrate new bonds resulting 
 
 
Figure 4. The impact of bone substitutes suspensions on the viability of S.aureus (A) and E.faecalis (B). Data are shown as a 




Figure 5. Disk diffusion test results of control (C), cHA500 
and cHA1000 against E. coli and S. aureus and E. faecalis, 
respectively. Data are shown as a mean ± standard deviation 
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from the modification of the surface of phosphates, which 
is indicative of the lack of introduction of ionic silver into the 
crystalline network of the phosphate. Moreover, the elemen-
tal analysis of the hydroxyapatite powders has demonstrated 
slight differences in Ca and P contents, which confirmed that 
the modification of the powders was superficial.  
 It is well known that silver nanoparticles exhibit an 
efficient antimicrobial activity which can be attributed to 
the high surface area providing a better contact with the 
microorganisms leading to enzymatic systems of the 
respiratory chain inhibition and alter DNA structure.[43] 
Another mechanism of antimicrobial reactivity of AgNPs is 
associated with the formation of free radicals and the 
release of silver ions which may lead to bacteria death.[44,45] 
Therefore, there are many scientific studies confirming the 
antibacterial activity of both ionic silver as well as their 
nanometric form.[46–48] 
 The study did not demonstrate a significant impact 
of the increased silver content in the suspension on the 
viability of E. faecalis. What is more, during incubation, only 
slight differences in the viability of E. faecalis were noted 
for cH500: 93.2 % ± 2.4, 87.1 % ± 3.1, and 81.8 % ± 1.7 after 
15, 30, and 60 minutes of incubation, respectively. 
Obtained results revealed no effect of increased silver 
content on a mild growth inhibitory effect even in higher 
AgNPs concentration. The low sensitivity observed in E. 
faecalis could probably be explained by the biochemical 
and physiological characteristics of this bacteria, which is 
well known for its high level of resistance to a wide range 
of antimicrobial agents. However, ex vivo studies on 
bactericide effect of silver nanoparticles on E. faecalis 
performed by González-Luna et al. show that nanoparticles 
of 10 nm (537 μg/mL) + EDTA (17 %) applied as a final 
irrigation agent were effective for eliminating E. faecalis 
[48]. The possible conclusion is that in the case of E. 
faecalis, the bactericidal properties strongly depend on the 
size of nanoparticles. Enterococci are recognized to be 
resistant to many antibiotics. In consequence of expression 
of low-affinity penicillin-binding proteins enterococci 
present increased resistance to most cephalosporins and 
penicillins. Moreover, enterococci are intrinsically resistant 
to clindamycin, trimethoprim-sulfamethoxazole, and amino-
glycosides. However, relatively rare resistance of E. faecalis 
to ampicillin and vancomycin does not preclude their 
clinical use. The best in vitro activity among of β-lactams 
utilizing in the treatment of E. faecalis infections is 
observed for aminopenicillins (ampicillin) and ureido-
penicillins (piperacillin), followed by carbapenems 
(imipenem).[49] It is worth emphasizing that the proportion 
of infections that are antibiotics resistant depends on the 
bacteria strain.[50] Ampicilline activity against various 
strains of E. faecalis bacteria was examined by Jonathan et 
al.[51] The minimal inhibitory concentration (MIC) and 
minimal bactericidal concentration (MBC) determined by 
the authors were in the range of 0.5–8 μg/mL and 4 –2048 
μg/mL, respectively. The studies on trimethoprim bacteri-
cidal effect on ten randomly selected E. faecalis strains 
were carried out by Crider et al.[52] In accordance with this 
research, the MICs values varied from 0.063 to 4 μg/mL, 
while MBCs were in the range of 0.25 μg/mL–4 μg/mL. In 
the case of E. coli and S. aureus, our experiments revealed 
a high inhibition of the growth of these bacteria. In 
accordance with results obtained by Li et al.,[53] it can be 
assumed that AgNPs at the concentration of 10 μg/mL (5 
nm) caused a total inhibition of respiratory chain 
dehydrogenases in E. coli. In light of the calculated yield of 
the surface modification of hydroxyapatite of 34.4 ug/mL 
for cHA500 and 54.6 ug/mL for cHA1000 resulting from the 
applied methods and of the size of nanoparticle 
agglomerates visible on SEM microphotographs, it may be 
concluded that due to high contents of Ag nanoparticles in 
the material, no viable bacterial cells were observed in the 
suspension. E. coli bacteria is a cause of a variety of noso-
comial and community-acquired bacterial diseases 
including infections of the enteric and urinary tract, surgical 
site infections, and sepsis as well as systemic infections in 
humans. Nowadays, aminopenicillins, fluoroquinolones, 
third-generation cephalosporins, aminoglycosides and 
carbapenems are typically use in E. coli infections treat-
ment.[54] However, in accordance with the current report 
regarding antimicrobial resistance in Europe, more than 
half of the reported E. coli isolates were resistant to at least 
one of the mentioned antimicrobial groups.[55] Anti-
microbial effect of ampicilline on E. coli (ATCC 25922) was 
describe by Septama et al.[56] According to their research, 
MIC and MBC were 0.9 μg/mL 1.95 μg/mL, respectively. 
Comparison of levofloxacin and gepotidacin bactericidal 
activity towards E. coli and S. aureus was performed by 
Flamm et al.[57] Gepotidacin is a novel triazaacenaphthylene 
antibiotic revealing activity against drug-resistant 
pathogens. The MBCs of gepotidacin for all of the S. aureus 
isolates tested were all 0.25 μg/mL, while MICs were 0.5 
μg/mL. The MBCs and MICs for the E. coli isolates examined 
were 2 μg/mL, and > 32 μg/mL, respectively. Levofloxacin 
bactericidal effect against S. aureus was strongly 
dependent on the strain type, while MBC and MIC values 
for E. coli were two times higher in comparison with 
gepotidacin. Performed by us antibacterial activity asses-
sment of AgNPs against S. aureus colony showed that 
growth inhibition exceeded 98 %, which may be linked to 
the lack of outer membrane characteristic of Gram(+) 
bacteria, which makes it easier for Ag nanoparticles to 
act.[53] The result was consistent with the study of 
antibacterial effects of silver nanoparticles on S. aureus 
obtained by Li et al.[58] which indicate lost replicating ability 
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The new approach for in situ preparation of hydroxyapatite 
surface modified with silver nanoparticles was developed 
to obtained antibacterial materials for wide application in 
the field of implantology and dentistry, especially in 
postoperative wound healing to prevent microbial 
infections. Taking into account the short time of 
production, the designed method can be considered as a 
new direction in effective antibacterial materials 
properties. No significant differences in crystal structure 
and chemical composition of cHA powders were indicated 
by XRD and FT-IR analysis, that confirmed no ionic 
substitution and chemical interaction between individual 
materials components. Additionally, SEM imaging 
demonstrated AgNPs presence on ceramic particles 
surface. Conducted research revealed antimicrobial 
properties of synthesized materials against E. coli and S. 
aureus. 
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